Table 1. Characteristics of 181.108 patients with breast cancer.
| Factors | Total (n = 181,108) | HR− (n = 32,684), No. (%) | HR+ (n = 148,424), No. (%) | p-value* | |
|---|---|---|---|---|---|
| Age (yr) | < 0.001 | ||||
| 20–40 | 15,085 | 4,498 (13.76) | 10,587 (7.13) | ||
| 40–60 | 95,690 | 18,753 (57.38) | 76,937 (51.84) | ||
| 60–70 | 41,066 | 5,975 (18.28) | 35,091 (23.64) | ||
| 70–80 | 29,267 | 3,458 (10.58) | 25,809 (17.39) | ||
| Race | < 0.001 | ||||
| White | 151,342 | 25,322 (77.48) | 126,020 (84.91) | ||
| Black | 14,122 | 4,605 (14.09) | 9,517 (6.41) | ||
| Others | 15,644 | 2,757 (8.44) | 12,887 (8.68) | ||
| Marital status | < 0.001 | ||||
| Married | 116,859 | 21,316 (65.22) | 95,543 (64.37) | ||
| Single | 22,135 | 4,246 (12.99) | 17,889 (12.05) | ||
| Divorce | 42,114 | 7,122 (21.79) | 34,992 (23.58) | ||
| Location | < 0.001 | ||||
| Central portion | 11,151 | 1,593 (4.87) | 9,558 (6.44) | ||
| Upper-inner quadrant | 23,335 | 4,263 (13.04) | 19,072 (12.85) | ||
| Lower-inner quadrant | 11,598 | 2,124 (6.50) | 9,474 (6.38) | ||
| Upper-outer quadrant | 77,828 | 14,591 (44.64) | 63,237 (42.61) | ||
| Lower-outer quadrant | 14,417 | 2,484 (7.60) | 11,933 (8.04) | ||
| Overlapping lesion | 42,779 | 7,629 (23.34) | 35,150 (23.68) | ||
| Histology | < 0.001 | ||||
| IDC | 154,829 | 31,585 (96.64) | 123,244 (83.04) | ||
| ILC | 11,453 | 383 (1.17) | 11,070 (7.46) | ||
| IDC+ILC | 14,826 | 716 (2.19) | 14,110 (9.51) | ||
| Differentiated grade | < 0.001 | ||||
| Well | 36,044 | 934 (2.86) | 35,110 (23.66) | ||
| Moderate | 81,582 | 6,639 (20.31) | 74,943 (50.49) | ||
| Poorly | 63,482 | 25,111 (76.83) | 38,371 (25.85) | ||
| T-classification† | < 0.001 | ||||
| T1 | 122,118 | 17,851 (54.62) | 104,267 (70.25) | ||
| T2 | 50,804 | 12,726 (38.94) | 38,078 (25.65) | ||
| T3 | 6,173 | 1,561 (4.78) | 4,612 (3.11) | ||
| T4 | 2,013 | 546 (1.67) | 1,467 (0.99) | ||
| N-classification† | < 0.001 | ||||
| N0 | 122,802 | 22,137 (67.73) | 100,665 (67.82) | ||
| N1 | 42,445 | 7,414 (22.68) | 35,031 (23.6) | ||
| N2 | 11,244 | 2,174 (6.65) | 9,070 (6.11) | ||
| N3 | 4,617 | 959 (2.93) | 3,658 (2.46) | ||
| Stage‡ | < 0.001 | ||||
| I | 94,737 | 13,896 (42.52) | 80,841 (54.47) | ||
| II | 67,134 | 14,771 (45.19) | 52,363 (35.28) | ||
| III | 19,237 | 4,017 (12.29) | 15,220 (10.25) | ||
| ER | - | ||||
| Negative | 36,111 | 32,684 (100.00) | 3,427 (2.31) | ||
| Positive | 144,997 | 0 | 144,997 (97.69) | ||
| PR | - | ||||
| Negative | 54,332 | 32,684 (100.00) | 21,648 (14.59) | ||
| Positive | 126,776 | 0 | 126,776 (85.41) | ||
| Radiotherapy | < 0.001 | ||||
| Without | 75,490 | 15,000 (45.89) | 60,490 (40.75) | ||
| With | 105,618 | 17,684 (54.11) | 87,934 (59.25) | ||
HR = hormone receptor; IDC = infiltrating duct carcinoma; ILC = infiltrating lobular carcinoma; ER = estrogen receptor; PR = prognosis receptor; AJCC = American Joint Committee on Cancer.
*p-values obtained from the χ2 test. All statistical tests were 2-sided, †Stage TNM, T, N-classification according to 8th edition of AJCC staging.